Butoconazole

Butoconazole

SCHEMBL44237

Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Butoconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 1.00
CYP3A4 P08684 5/20 1.00
CYP2D6 P10635 5/20 1.00
CYP2C9 P11712 5/20 1.00
CYP2C19 P33261 5/20 1.00
ALOX15 P16050 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
NR1I2 O75469 3/20 1.00
NR3C1 P04150 3/20 1.00
ADORA3 P0DMS8 3/20 1.00
ADRA2B P18089 3/20 1.00
CHRM3 P20309 3/20 1.00
OPRK1 P41145 3/20 1.00
SLC6A3 Q01959 3/20 1.00
PDE4D Q08499 3/20 1.00
KCNH2 Q12809 3/20 1.00
AGTR1 P30556 2/20 1.00
LMNA P02545 2/20 1.00
TSHR P16473 2/20 1.00
PGR P06401 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butoconazole SCHEMBL44239 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Butoconazole SCHEMBL44238 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Butoconazole SCHEMBL29091982 0.99 CYP1A2 (0.98) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Butoconazole SCHEMBL41394 0.92 L3MBTL1 (1.00) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Butoconazole SCHEMBL41395 0.92 L3MBTL1 (1.00) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL14340044 0.92 CYP1A2 (0.85) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Butoconazole SCHEMBL28464029 0.91 ALDH1A1 (0.83) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL11633431 0.91 ALDH1A1 (0.83) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL11442840 0.91 ALDH1A1 (0.83) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL11633890 0.91 ALDH1A1 (0.83) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 13293 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106952-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION CDG CARE (US) 2026-05-21 WO claimed
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
US-20260102419-A1 USE OF COMPOUNDS IN THE TREATMENT OF FUNGAL INFECTIONS BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2026-04-16 US claimed
EP-4719384-A2 COMPOUNDS WITH ANTIFUNGAL PROPERTIES Trustees of Dartmouth College (US) 2026-04-08 EP claimed
US-20260027140-A1 COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA ATOPIC MEDICAL INC (US) 2026-01-29 US claimed
EP-4680240-A1 METHOD OF TREATING DISORDERS WITH SURF1 MALFUNCTION Cure Mito Foundation (US) 2026-01-21 EP claimed
EP-4676500-A2 MICROBIAL CONSORTIA Kanvas Biosciences, Inc (US) 2026-01-14 EP claimed
EP-4659014-A1 EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING President And Fellows Of Harvard College (US) 2025-12-10 EP claimed
US-20250268998-A1 METHODS OF TREATMENT FOR CANDIDA AURIS INFECTIONS LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER 2025-08-28 US claimed
US-12383566-B2 Inhibition of SLC transporter activity or expression to attenuate anthracycline-induced cardiotoxicity NORTHWESTERN UNIVERSITY (US) 2025-08-12 US claimed
US-5214046-A Synergistic mixtures, inhibitors of sterol biosynthesis HOFFMANN-LA ROCHE INC. (US) 1993-05-25 US claimed
EP-0538442-A1 METHOD FOR IMPROVING THE THERAPEUTIC EFFICIENCY OF LIPOSOLUBLE ANTIFUNGAL AGENTS FROM THE IMIDAZOLE FAMILY, AND COMPOSITION FOR IMPLEMENTING SAME. OREAL (FR) 1993-04-28 EP claimed
WO-1992019225-A1 METHOD FOR IMPROVING THE THERAPEUTIC EFFICIENCY OF LIPOSOLUBLE ANTIFUNGAL AGENTS FROM THE IMIDAZOLE FAMILY, AND COMPOSITION FOR IMPLEMENTING SAME L'OREAL (FR) 1992-11-12 WO claimed
EP-0310122-B1 ANTIFUNGAL COMPOSITION KAKEN PHARMACEUTICAL CO., LTD. (JP) 1991-07-24 EP claimed
EP-0187702-B1 N-(OMEGA,OMEGA-1-DIALKOXY)- AND N-(OMEGA,OMEGA-1-DIALKENOXY)-ALK-1-YL-N,N,N-TRISUBSTITUTED AMMONIUM SURFACTANTS, THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM SYNTEX (U.S.A.) INC. (US) 1990-03-14 EP claimed
EP-0310122-A1 Antifungal composition KAKEN PHARMACEUTICAL CO., LTD. (JP) 1989-04-05 EP claimed
EP-0187702-A1 N-(omega,omega-1-dialkoxy)- and N-(omega,omega-1-dialkenoxy)-alk-1-yl-N,N,N-trisubstituted ammonium surfactants, their preparation and pharmaceutical formulations containing them SYNTEX (U.S.A.) INC. (US) 1986-07-16 EP claimed
US-4277475-A FOR BOTH MALES AND FEMALES SYNTEX (U.S.A.) INC. (US) 1981-07-07 US claimed
US-4247552-A Contraceptive compositions and methods employing 1-substituted imidazole derivatives SYNTEX (U.S.A.) INC. (US) 1981-01-27 US claimed
US-4078071-A FUNGICIDES, BACTERICIDES, ANTIPROTOZOA AGENTS SYNTEX (U.S.A.) INC. (US) 1978-03-07 US claimed